Prospects for Foamy Viral Vector Anti-HIV Gene Therapy

Arun K Nalla; Grant D Trobridge

doi:10.3390/biomedicines4020008

Prospects for Foamy Viral Vector Anti-HIV Gene Therapy

Biomedicines. 2016 Mar 29;4(2):8. doi: 10.3390/biomedicines4020008.

Authors

Arun K Nalla¹, Grant D Trobridge^{2

3}

Affiliations

¹ Pharmaceutical Sciences, College of Pharmacy, Washington State University Spokane, Spokane, WA 99202, USA. arun.nalla@wsu.edu.
² Pharmaceutical Sciences, College of Pharmacy, Washington State University Spokane, Spokane, WA 99202, USA. grant.trobridge@wsu.edu.
³ School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA. grant.trobridge@wsu.edu.

Abstract

Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV.

Keywords: anti-HIV transgenes; foamy viruses; gene therapy; retroviral vector.

Publication types

Review

Abstract

Publication types

Grants and funding